Guidance, NICE advice and quality standards in development | Guidance

Showing 311 to 320 of 392

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Selpercatinib for advanced thyroid cancer with RET alterations after treatment with a cancer drug in people 12 years and over (managed access review of TA742) [ID6288]	Technology appraisal guidance	TBC
Selpercatinib for advanced thyroid cancer with RET alterations that has not been treated with systemic therapy [ID6132]	Technology appraisal guidance	TBC
Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer (MA review of TA760) [ID6293]	Technology appraisal guidance	TBC
Selpercatinib for treating RET fusion-positive advanced solid tumours in people aged 12 and over with no other treatment options [ID6273]	Technology appraisal guidance	TBC
Selpercatinib for untreated RET-positive advanced thyroid cancer [ID6183]	Technology appraisal guidance	TBC
Semaglutide for preventing major cardiovascular events in people with cardiovascular disease and living with overweight or obesity ID6441	Technology appraisal guidance	TBC
Serplulimab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer ID6346	Technology appraisal guidance	TBC
Sipavibart for preventing COVID 19 [ID6282]	Technology appraisal guidance	TBC
Sirolimus gel for treating facial angiofibroma from tuberous sclerosis complex in people 6 years and older (review of TA972) [ID6440]	Technology appraisal guidance	12 November 2025
Slide sheets for repositioning or moving a person on or from a bed: Late Stage Assessment	Health technology evaluation	28 May 2025